Europe Peripheral Vascular Angiography Contrast Media Market Report: Market Size & Forecast 2026

The European peripheral vascular angiography contrast media market covers the segment of contrast agents used specifically in peripheral angiography procedures, imaging tests that help clinicians diagnose blockages and narrowing in the arteries and veins of the legs, arms, kidneys, and other peripheral regions. Iodinated contrast media, the dominant type, is administered intravenously before X-ray or CT-based angiography to improve the visibility of blood vessels. The market forms a key component of the broader European contrast media landscape and is closely tied to the performance of the European angiography devices and peripheral vascular devices markets, which together reflect growing procedural volumes.

• •The broader European contrast media market is projected to reach USD 3.19 billion by 2031, supported by demand across CT, X-ray, and angiography imaging modalities.
• •The European angiography devices market was estimated at USD 3.75 billion in 2025 and is projected to grow to USD 5.60 billion by 2032 at a 5.80% CAGR, driving corresponding demand for contrast agents.
• •The European peripheral vascular devices market reached USD 2.65 billion in 2023 and is expected to grow to USD 4.18 billion by 2032, reflecting rising rates of peripheral artery disease interventions.

A primary growth catalyst is the rising prevalence of peripheral artery disease (PAD) across Europe, driven by aging demographics and increasing rates of diabetes, smoking-related conditions, and sedentary lifestyles. Technological advancements in angiography imaging systems, including flat-panel detectors, rotational angiography, and hybrid OR suites, are enabling more precise diagnostics and creating demand for high-quality contrast agents. Growing adoption of minimally invasive endovascular procedures over open surgical alternatives is expanding procedural volumes. Favorable reimbursement policies for interventional radiology and angiography in major European health systems continue to support market expansion.

• •The aging European population is a significant driver, as PAD prevalence rises sharply in individuals over 65, leading to higher angiography and contrast media utilization rates.
• •Increasing preference for minimally invasive diagnostics and treatment of vascular disease is shifting clinical workflows toward angiography-based procedures.
• •Advances in multi-detector CT angiography and digital subtraction angiography systems are improving diagnostic accuracy and expanding the addressable patient population.

The market is segmented by contrast media type, including iodinated non-ionic, iodinated ionic, gadolinium-based agents, and CO2-based contrast media, with iodinated non-ionic agents holding the dominant share in peripheral angiography. Application segments include diagnostic angiography, interventional procedures, and CT angiography. Western Europe, particularly Germany, France, the United Kingdom, and Italy, accounts for the largest regional share due to higher healthcare spending, advanced clinical infrastructure, and greater procedural adoption rates. Central and Eastern European markets are growing at faster relative rates as healthcare systems modernize and access to interventional radiology services expands.

• •Germany and France are among the largest individual country markets in Europe, driven by high volumes of vascular interventions and strong hospital infrastructure.
• •The United Kingdom's NHS has maintained steady angiography procedure growth, supported by national vascular surgery and interventional radiology quality improvement programs.
• •Eastern European markets, including Poland, Czech Republic, and Turkey, represent emerging growth opportunities as healthcare spending rises and angiography services extend beyond major metropolitan centers.

What are the recent trends and outlook?

The market outlook through 2030 remains positive, supported by compounding demand from an aging European population, continued expansion of endovascular therapy programs, and the integration of artificial intelligence into angiography imaging workflows. Emerging trends include the development of iso-osmolar contrast agents with improved safety profiles for high-risk patient populations, the adoption of dual-energy CT angiography to reduce contrast doses, and growing interest in carbon dioxide angiography as an alternative for patients with renal impairment. Supply chain localization efforts and European domestic manufacturing incentives are expected to reshape procurement patterns over the forecast period, potentially favoring regional suppliers.

• •Development of next-generation iso-osmolar contrast agents with lower nephrotoxicity profiles is expected to drive premium product adoption in Europe's aging patient population.
• •Integration of AI-assisted image interpretation in angiography suites may expand the diagnostic utility of contrast-enhanced peripheral vascular imaging and broaden market demand.
• •Carbon dioxide (CO2) angiography is gaining clinical acceptance as a contrast-free alternative for patients with severe chronic kidney disease, representing an emerging niche within the broader market.